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attention to the radiotherapy planning and delivery 
elements, and careful systematic and prospective 
documentation of tumor and normal tissue outcomes. Even if 
randomised trials are deemed unsuited to the setting, 
protocol based approaches in registered phase I/II trials are 
appropriate to enhance standards and should probably 
include audit and quality assurance processes, as well as 
realistic stopping rules to address unexpected or aberrant 
outcomes. 
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Proton therapy is a radiation modality that has become 
increasingly available world wide over the past decade. It is 
an attractive radiotherapy intervention because of the 
charged particles dose deposition profile of characterized by 
the Bragg peak. By using proton therapy strategically, there 
is the possibility to deliver effective radiation dose to the 
target while reducing radiation to the surrounding non-target 
structures. The goals of any radiotherapy approach is to 
improve tumor control and/or reduce side effects and proton 
therapy offers an opportunity to achieve either one or both 
of these goals.Despite the promise of proton therapy, one 
must consider its associated risks and benefits, and as with 
any other radiation approach, to maximize the benefit to the 
patient. In general concepts that are useful in selecting and 
predicting a the benefit of proton therapy in individual 
patients include the following:  
1) Proton therapy has the same risk of injury within the 
target area and high dose as other radiation therapies. For 
infiltrative tumors that require irradiation of a margin of 
normal tissue (example rhabdomyosarcoma) or those that 
have normal cells embedded within the tumor (example low 
grade glioma), the tissues receiving the high dose of 
radiotherapy will have similar risks of injury as non-proton 
approaches; therefore, one would not expect a lower risk of 
injury in the high dose area.  
2) Since proton therapy is typically associated with a lower 
risk of late effectsPatient who has a very low chance of 
surviving a long time due to the natural history of the 
disease, may not benefit from proton therapy, example 
widely metastatic cancer.  
3) Patients, for example children, who can derive benefit 
from normal tissue radiation dose reduction are usually good 
candidates  
4) Patients who require high doses of radiation to achieve 
tumor control, but would otherwise be limited due to normal 
tissue tolerance, for example patients with skull base 
chordoma or primary or secondary liver.  
5) Tumor geometry and surrounding anatomy must be 
evaluated to estimate the potential benefit of proton 
therapy. For example, a 2 year old patient requiring flank 
radiation for Wilms tumor may have not benefit with proton 
therapy, whereas an 18 year old with a paravertebral Ewing's 
sarcoma may have significant advantage with proton therapy.  
6) Patient set up, tissue uncertainties, external devices or 
implanted need to be evaluated to minimize the risk of 
uncertainties and disruption in the proton dosimetry.  
7) Proton therapy may be a good option for re-irradiation in 
selected patients.In summary, proton therapy can be an 
excellent option to provide better local control and/or 
reduced toxicities in selected patients.  
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Intensity Modulated Proton therapy (IMPT) is a highly 
promising approach for radiation treatment of cancer 
patients due to its increased potential to reduce side effects 
and improve quality of life compared to contemporary 
radiation therapy techniques, such as IMRT. However, IMPT is 
associated with high costs and hence limited availability. 
Ideally, patient selection for IMPT should be based on the 
highest expected complication reduction compared to IMRT. 
For a given patient, it is possible to predict the risk of side 
effects for proton and photon therapy by applying Normal 
Tissue Complication Probabilities (NTCP) models to optimized 
dose distributions. Only patients with clinically relevant 
reductions in NTCP exceeding minimum pre-defined 
thresholds will then qualify for proton therapy. While this 
approach should guarantee effective use of proton therapy, 
there are several concerns that will be discussed in this 
presentation: 
1. The generation of a radiotherapy treatment plan is a 
complex procedure and its quality is highly dependent on the 
planner skills. To enable unbiased comparisons between IMPT 
and IMRT for each patient, automation of the treatment 
planning process is imperative. 
2. IMPT is highly susceptible to inaccuracies in patient setup, 
anatomic changes, and to uncertainties in the calculation of 
the proton range. In IMRT, uncertainties in dose delivery are 
accounted for in the CTV-to-PTV margin. In IMPT, however, 
the PTV concept is not applicable. Alternatively, robust 
treatment planning can be used to take into account patient 
setup and range uncertainties. However, it is currently 
unknown which robustness settings need to be used to 
achieve an adequate target coverage for given population-
based distributions of setup and range errors. 
3. Image-guidance technology improves the accuracy of 
radiation therapy delivery, however its impact and current 
state-of-the-art may vary for proton and photon radiotherapy 
due to the physical differences between protons and photons 
and for historical reasons. The applied image-guidance 
technology will have an impact on the magnitude of NTCP 
reduction and hence on the selection of patients qualifying 
for proton therapy. 
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The last decade, many new radiation delivery techniques 
have been clinically introduced without being subjected to 
randomized controlled trials. Many of these new techniques 
have been introduced in order to reduce the dose to the 
healthy tissues and subsequently to prevent radiation-
induced side effects. Due to its superior beam properties, 
radiotherapy with protons compared to photons enables 
similar dose administration to the target volume with 
substantially lower dose to the normal tissue. In the 
Netherlands, we applied a 4-step model-based approach to 
select patients for proton therapy and to validate the benefit 
of protons compared to photons with regard to reducing the 
risk on radiation-induced side effects.  
Step 1 consists of the development and validation of 
multivariable Normal Tissue Complication Probability (NTCP) 
models. NTCP models describe the relationship between 
radiation dose distribution parameters and the probability of 
a given side effect (NTCP-value). One of the output 
parameters of this step are the most relevant Dose Volume 
Histogram (DVH) parameters that can be used to optimize 
radiation treatment.  
Step 2 includes in silico planning comparative studies. In this 
phase protons are compared with photons with regard to 
their ability to reduce the most relevant DVH-parameters 
resulting from step 1 (∆Dose).  
Step 3: Integration step 1 and 2. By integrating the results of 
the individual in silico planning comparison into the validated 
NTCP-models, the differences in dose can be translated into 
a difference in NTCP-value in each individual patient 
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(∆NTCP). In the Netherlands, a national consensus has been 
reached regarding the threshold for (∆NTCP  
Finally, the potential benefits of protons can be clinically 
validated in step 4, based on external validation of the NTCP-
models when patients are treated with protons. The model-
based approach is an evidence-based methods for selection 
and validation of new radiation technologies. 
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Synopsis:  
In thoracic irradiation, the maximum radiation dose is 
restricted by the risk of radiation-induced cardiopulmonary 
damage and dysfunction limiting tumor control. 
Unfortunately, current clinical practice does not include 
preventative measures to attenuate radiation-induced lung or 
cardiac toxicity. Inhibition of the renin-angiotensin system 
(RAS) seems to be an alluring strategy for attenuating 
radiation-induced cardiopulmonary dysfunction.  
Interestingly, angiotensin-converting enzyme inhibitors (ACEi) 
have been shown to reduce the risk of radiation-induced 
respiratory dysfunction in preclinical (1) and clinical studies 
(2). More recently a study in rats showed that ACEi reduces 
respiratory dysfunction indirectly by reducing acute heart 
damage (3).  
So far, the mechanisms of the protective effect of ACEi on 
radiation-induced toxicity are not clear. Apart from their 
hypotensive action, ACEi are known to have other properties 
such as an anti-inflammatory action. Further, it has been 
suggested that the sulfhydryl group in the molecular 
structure of captopril confers in a free radical scavenger 
activity. All these effects can account in part for its 
radioprotection. Besides, it might act as an antioxidant to 
reduce inflammatory reactive oxygen species and thus 
mitigate radiation-induced toxicity.  
To conclude, ACE inhibitors have been shown to mitigate 
radiation-induced cardio-/pulmonary toxicity in (pre)clinical 
models. However, the mechanisms of action are not clear. As 
such the use of ACE inhibitors should be further evaluated as 
a strategy to reduce cardiopulmonary complications induced 
by radiotherapy to the thoracic area.  
1. Ghosh SN, Zhang R, Fish BL, et al. Renin-angiotensin 
system suppression mitigates experimental radiation 
pneumonitis. Int J Radiat Oncol Biol Phys 2009;75:1528-36.  
2. Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of 
radiation pneumonitis with incidental concurrent use of 
angiotensin-converting enzyme inhibitors and thoracic 
radiation therapy. Int J Radiat Oncol Biol Phys 2012;84:238-
43.  
3. van der Veen SJ, Ghobadi G, de Boer RA, et al. ACE 
inhibition attenuates radiation-induced cardiopulmonary 
damage. Radiother Oncol 2015;114:96-103. 
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RI musculo-squeletic sequelae combine opposite tissular 
aspects of fibrosis and atrophy in an heterogeneous 
patchwork comprising concomitant active cellular and 
sclerotic matricial areas. Tissue remodeling follow early, 
subacute, chronic inflammatory changes, then fibrosis and 
necrosis, that provides signaling pathways through growth 
factors and their receptors.  
In medicine, clinical cure of a chronic disease is never binary 
or surgical, if exists, because of the pathologic underground 
network well-established in the tissues.  
Cure for radiation-induced (RI) late damages should be 
approach by a strategy using a hierarchical control of 
accurate protagonists. During last decades, each therapeutic 
intervention has illustrated successively one of the facets of 
this fibrotic process:  
- In seventies, STEROIDS, then non anti-inflammatory drugs, 
showed able to stop acute RIF progression and are always 
required today as the first treatment in all sequelae, while 
anti-collagenic drugs were too toxic.  
- In eighties, vascular approach revealed antithrombotic help 
in some acute aspects (HEPARIN), and interesting role of 
PENTOXIFYLLINE (speed healing) or HBO.  
- In nineties, successful clinical use of superoxide dismutase 
(SOD) allowed to bring to light reactive oxygen species (ROS) 
- fibroblasts and their related anti-oxidant strategy, then 
PENTOXIFYLLINE-VITAMIN E (PE) combination. The fibrotic 
clinical regression was slow but measurable, followed by 
convincing “preclinical” studies (histological reversion, in 
vitro modulation): first cases of fibrotic clinical cure [1,2].  
- Then anticytokines (TGFβ, CTGF, …).  
- After 2000, adding clodronate, in a PENTOCLO combination, 
allowed speeder and durable clinical RI responses, 
highlighting its anti-macrophagic effect on bone necrosis : 
first cases of osteoradionecrosis clinical cure [3]. However, 
therapeutic range of these drugs is tight, related to 
bisphosphonate absence of specificity and the bivalent 
macrophagic action (M1/M2 populations).  
Clinical cure is a difficult art: it should take in account all 
these several facets. In the future, controlled trials and 
preclinical studies are necessary to identify best antifibrotic 
agents (phenotypic revesion of deficient cells), and organ 
specific targeted drugs and/or stem cell therapy (compensate 
tissular depletion after cell death), to obtain regular clinical 
cure if any.  
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